Preventing hepatitis B reactivation after stem cell transplant
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This trial tests whether taking the antiviral medicine entecavir before and after a stem cell transplant can prevent hepatitis B from “waking up” again. It may help protect your liver during a high-risk treatment period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 19 to 70 years old
- You are receiving an allogeneic stem cell transplant (from a donor, not your own cells)
- Before transplant, your blood tests show HBsAg negative and anti-HBc IgG positive (past hepatitis B infection)
- You can do daily activities fairly normally (ECOG 0 to 2)
- You agree to join the study (sign informed consent)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks patients who carry hepatitis B antibodies and are about to start immunosuppressive therapy (medications that weaken the immune system). Researchers want to understand when and how hepatitis B can reactivate in these patients and how to prevent it.
This study looks at people who had hepatitis B in the past (but are not currently infected) and are getting a stem cell transplant. The goal is to see if a simple model can predict whether the hepatitis B virus might come back, so doctors can monitor and treat it early.
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
This trial tests whether giving the antiviral drug entecavir before or at the first sign of hepatitis B reactivation can prevent liver problems in gastrointestinal cancer patients who are inactive hepatitis B carriers and are starting chemotherapy or immunotherapy.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This study looks at the best time to give the hepatitis B vaccine after a stem cell transplant. It may help your body build protection against hepatitis B more effectively after your transplant.
Hear when a new Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.